ACADIA Pharmaceuticals (ACAD)
(Delayed Data from NSDQ)
$16.71 USD
+0.40 (2.45%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $16.71 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum A VGM
Price, Consensus and EPS Surprise
ACAD 16.71 +0.40(2.45%)
Will ACAD be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ACAD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ACAD
Why Is Acadia (ACAD) Down 23.4% Since Last Earnings Report?
Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
ACAD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Acadia (ACAD) Down as Schizophrenia Study on Nuplazid Fails
Acadia (ACAD) Q4 Earnings Lag, Sales Beat Estimates, Stock Down
Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates
Other News for ACAD
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
Acadia Pharmaceuticals announces Health Canada acceptance of trofinetide NDS
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting